MOU7 Feb 2023 12:53
RNS 23 Nov 2023 (extract below. Any idea when the next update might be due?
'The new MOU reflects progress by iCCAMT to implement a clinical pilot study to evaluate optimised assays using a monoclonal antibody that Cizzle Biotechnology has developed that specifically detects CIZ1B, which is highly associated with stage 1 lung cancer. The initial pilot clinical studies will be conducted at the Cancer Hospital Chinese Academy of Medical Sciences, National Cancer Center of China. These results will have the potential to provide a platform for developing full commercial tests that can be made available throughout China.'
Commenting, Dr Hui Wu, CEO and Founder of iCCAMT said:
'This new MOU is an important document covering new progress from both sides and we are now prepared and ready to commence clinical pilot studies. The new monoclonal CIZ1B antibody developed by our British partner is now being optimized in assays to be delivered to the National Cancer Center of China in Beijing, and iCCAMT has been collaborating on the design of a pilot clinical study proposal with leading clinical researchers from the center. We are looking forward to continuing our partnership and to securing successful outcomes in the near future.'